Date:8/9/2011

rimarily due to the decline in lower margin sales to Nagase Landauer.  Selling, general and administrative costs for the first nine months of fiscal 2011 increased 8 percent, or $1.7 million, to $23.1 million.  The increase is due primarily to $0.7 million of costs to replace the Company's IT systems and related depreciation, $0.9 million of increased international spending to support international revenue growth and $0.4 million from the strengthening of most foreign currencies against the dollar, partially offset by a decline in compensation benefits.  Operating income, inclusive of the impact of acquisition related transaction and reorganization costs, for the nine months ended June 30, 2011 increased 3 percent, or $0.6 million, to $28.4 million compared with operating income of $27.8 million for the same period in fiscal 2010.

Medical Physics SegmentMedical Physics revenues for the first nine months of fiscal 2011 increased 53 percent, or $5.1 million, to $14.6 million on $2.3 million of organic growth and $2.8 million due to the impact of acquired companies.  The gross margin declined to 23 percent from 24 percent in the year ago period.  Selling, general and administrative costs for the first nine months of fiscal 2011 increased 37 percent, or $1.1 million, to $4.0 million.  The increase is due to the impact of acquired companies and costs to support organic growth.  Operating loss was $0.6 million for each of the nine months ended June 30, 2011 and 2010, respectively.

Solid Financial PositionLandauer ended the third fiscal quarter of 2011 with total assets of $160.9 million.  Due to the current liability classification of $12.9 million in outstanding borrowings incurred to support the acquisitions completed during the first fiscal quarter of 2010, the Company had negative working capital of $7.4 million.  The Company believes projected operating cash flow and available borrowing under its
'/>"/>

SOURCE Landauer, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2010 Results
2. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results
3. Landauer, Inc. Declares Regular Cash Dividend
4. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2011 Results
5. Landauer, Inc. Declares Regular Cash Dividend
6. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Second Quarter 2011 Results
7. Landauer, Inc. Declares Regular Cash Dividend
8. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2011 Results
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results